12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

MaterniT21 PLUS laboratory-developed test regulatory update

The not-for-profit California Technology Assessment Forum (CTAF) recommended use of Sequenom's MaterniT21 PLUS laboratory-developed test (LDT) to detect prenatal fetal chromosomal anomalies. Specifically, CTAF said the test meets criteria for safety, efficacy and improvement in health...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >